Search for either of these compounds and you land in a strange corner of the internet where two peptides are treated as interchangeable siblings, one slightly newer than the other. That framing is wrong in a way that matters. One of them has an approved indication, two published phase 3 trials, and a brand name still on pharmacy shelves. The other was pulled from the US market in 2008 and has almost no modern adult trial data behind it.
Which is not the same as saying one is good and one is bad. They were developed for genuinely different reasons. This is a comparison of what sermorelin and tesamorelin are, what the research on each actually covers, and where the evidence runs out.
Sermorelin vs tesamorelin: the short version
Both are analogs of growth hormone-releasing hormone, or GHRH, the signal the hypothalamus sends to the pituitary telling it to release growth hormone. Neither is growth hormone itself. That distinction is the entire point of the category, because a GHRH analog prompts the pituitary to release its own GH in the body’s normal pulsatile rhythm, while injected HGH overrides that rhythm entirely.
| Sermorelin | Tesamorelin | |
|---|---|---|
| What it is | GHRH (1-29), the shortest fragment that retains activity | Stabilized GHRH (1-44) analog |
| Brand name | Geref | Egrifta |
| FDA status | Approved 1997, withdrawn from the US market in 2008 | Approved 2010, still marketed |
| Approved use | Pediatric growth hormone deficiency | Reduction of excess visceral fat in HIV-associated lipodystrophy |
| Plasma half-life | Roughly 10 to 20 minutes | Roughly 26 to 38 minutes |
| Phase 3 trial data in adults | Minimal | Two trials, roughly 800 participants |
| Stocked at Healio | No | Yes |
If you only read the table, the useful takeaway is that these two compounds sit at very different points on the evidence curve, and most of the content comparing them does not mention that at all.
What sermorelin is, and why it left the US market
Sermorelin is the first 29 amino acids of human GHRH. Natural GHRH is 44 amino acids long, and researchers established decades ago that the biological activity lives almost entirely in that first stretch. Everything after residue 29 turned out to be largely structural.
It was approved in 1997 under the brand name Geref, used both to diagnose growth hormone deficiency in children and to treat it. Then in 2008 the manufacturer discontinued it.
Here is the part that gets misreported constantly: the withdrawal was a commercial decision, not a safety action. Recombinant human growth hormone had taken over the market, the pediatric indication was small, and the product stopped making sense to manufacture. No black box warning, no recall, no adverse event cascade. It simply stopped being worth making.
What that leaves behind is a compound with a reasonable safety history and a research base that mostly predates the year 2000. Sermorelin is still available through compounding pharmacies and is widely marketed by wellness clinics, which is why it shows up in so many comparison articles despite having very little contemporary trial evidence in adults.
What tesamorelin is and what it was approved to do
Tesamorelin took a different route. It is full-length GHRH (1-44) with a trans-3-hexenoyl group attached to the N-terminus, and that modification is doing real work. Native GHRH is degraded rapidly in plasma by the enzyme DPP-4. The added group blocks that cleavage site, which is why tesamorelin survives roughly twice as long in circulation.
The FDA approved it in 2010 under the brand name Egrifta, for one specific and narrow indication: reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy. That is a condition where antiretroviral therapy drives fat accumulation deep in the abdominal cavity, around the organs rather than under the skin, and it had no good treatment.
The approval rested on two phase 3 trials. The first was published in the New England Journal of Medicine in 2007 by Falutz and colleagues, the second followed in 2008. Across roughly 800 participants, 26 weeks of tesamorelin produced visceral adipose tissue reductions in the range of 15 to 18 percent compared with placebo, measured by CT scan rather than by tape measure.
Worth noting what the trials also found: the effect reversed when treatment stopped. Participants who discontinued regained visceral fat over the following six months. That is a finding the marketing copy tends to leave out, and it is arguably the most important number in the entire dataset.
Sermorelin vs tesamorelin: how the two molecules actually differ
A note on terminology, because this trips up almost every article on the subject. You will see sermorelin described as a “GHRF analog” and tesamorelin as a “GHRH analog,” presented as though they act on different systems. They do not. GHRF and GHRH are two names for the same hormone, growth hormone-releasing factor and growth hormone-releasing hormone. Both compounds bind the same pituitary receptor.
The genuine differences are three, and they are all about durability and depth of evidence.
Length and stability. Sermorelin is a truncated fragment with no protective modification, so DPP-4 clears it quickly. Tesamorelin is full length with a blocking group, so it does not.
Where the research was aimed. Sermorelin’s evidence base was built around pediatric growth. Tesamorelin’s was built around abdominal visceral fat in adults, which is why almost everything written about it now circles back to body composition.
Regulatory standing. One product has a current FDA label with a full prescribing information document. The other has a label that stopped being maintained in 2008.
What the tesamorelin research covers that the sermorelin research does not
Beyond visceral fat, the tesamorelin literature has gone in directions the sermorelin literature never did.
Trials have looked at liver fat, with a 2019 study in Lancet HIV reporting reduced hepatic fat fraction and less progression of fibrosis in people with HIV and nonalcoholic fatty liver disease. Others have examined cognitive measures in older adults with mild cognitive impairment, and lipid profiles alongside the body composition endpoints.
Two honest limits sit on all of it. Nearly every trial was conducted in a specific clinical population, usually people living with HIV, and findings in that group do not transfer automatically to healthy adults. And no trial has run long enough to say anything useful about multi-year use.
Sermorelin, by contrast, has essentially no equivalent modern body of adult research. That is not a claim that it does nothing. It is a claim that nobody has properly checked, which is a different and slightly more frustrating problem.
To be fair to it, the older work exists and is not nothing. Groups at Johns Hopkins and elsewhere ran GHRH (1-29) studies in healthy older adults through the 1990s, reporting increases in IGF-1 and modest shifts in lean mass and fat mass over several months. Those studies were small, ran short, and were designed around the question of whether GHRH could substitute for growth hormone in age-related decline. Then the field moved on, funding followed recombinant HGH, and the follow-up trials that would have settled anything never happened.
So the honest summary is that sermorelin is under-researched rather than disproven. Whether that reads as a red flag or as an open question probably depends on how much patience you have for open questions.
Tesamorelin and sermorelin for women: what the sex differences change
Growth hormone physiology is not the same across sexes, and this is one of the few places where a peptide comparison genuinely needs a separate paragraph rather than a bolted-on afterthought.
Women secrete GH in pulses of higher amplitude and more continuously than men do. Estrogen also suppresses hepatic IGF-1 production, so the same GH signal produces a lower circulating IGF-1 response. In practice, that means an identical GHRH stimulus can produce measurably different downstream results depending on estrogen status, and estrogen status changes considerably through the perimenopausal transition.
The tesamorelin phase 3 trials did include women, which is more than can be said for a lot of peptide research. Subgroup analyses have reported that women in those trials showed a smaller IGF-1 rise than men at comparable exposure. Whether that is a meaningful difference or a statistical curiosity has not been resolved.
This is exactly the gap that makes the category worth writing about carefully rather than enthusiastically. Anyone telling you how a GHRH analog behaves in women specifically is working from a thinner evidence base than the confidence in their voice suggests.
What both peptides share, including the risks
Because both act on the same receptor, the reported effect profiles overlap heavily. The most commonly documented in the tesamorelin trials were injection site reactions, joint pain, peripheral swelling from fluid retention, and muscle aches.
The one that deserves real attention is glucose. Growth hormone opposes insulin action, so raising GH raises the risk of impaired glucose tolerance. The tesamorelin prescribing information addresses this directly, and it is not a footnote. Both compounds also raise IGF-1, which is the intended downstream effect and simultaneously the reason long-term data would be valuable.
Neither is an anabolic steroid, and neither works like one. They act on the pituitary, not on androgen receptors.
There is also a category of person for whom raising IGF-1 is a bad idea on its face, and the tesamorelin label says so plainly: active malignancy is a contraindication, because IGF-1 is a growth signal and growth signals do not distinguish between tissue you want and tissue you do not. Diabetic retinopathy is another. These are not obscure edge cases, and they are the sort of detail that gets stripped out of a comparison article aimed at selling a consultation.
Where to source tesamorelin, and why sermorelin is not on this site
Healio stocks tesamorelin and does not stock sermorelin. That is a deliberate choice rather than a supply gap: the evidence base behind one of them is substantially deeper, and stocking a compound whose adult research mostly predates the millennium is hard to justify.
Whatever you source and wherever you source it, the certificate of analysis is the thing to check. Third-party lab, batch number matching the vial, purity by HPLC, identity by mass spectrometry. Healio publishes every batch certificate openly at the research page before purchase rather than on request afterward. Tesamorelin sits in the weight loss peptide collection alongside the GLP-1 class compounds, which work through an entirely unrelated mechanism and are worth understanding separately. If you have not handled lyophilized material before, the reconstitution guide covers the bench procedure.
Sermorelin vs tesamorelin: frequently asked questions
Is tesamorelin FDA approved?
Yes, for one narrow indication. The FDA approved tesamorelin in 2010 under the brand name Egrifta for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It has no approval for general weight loss, anti-aging, or athletic use, and material sold for research purposes is not the approved pharmaceutical product.
What does tesamorelin do?
It binds the pituitary GHRH receptor and prompts release of the body’s own growth hormone, which in turn raises IGF-1. In its phase 3 trials that translated into reductions in visceral adipose tissue of roughly 15 to 18 percent over 26 weeks, measured by CT. The effect reversed after treatment ended.
Can tesamorelin and sermorelin be combined?
No published trial has studied the combination. Both bind the same pituitary receptor, so there is no mechanistic reason to expect an additive effect from stacking two agonists at one target. The idea circulates widely in clinic marketing and has no research behind it.
Is tesamorelin a steroid?
No. Tesamorelin is a peptide analog of a naturally occurring hypothalamic hormone. It acts on the pituitary GHRH receptor rather than on androgen receptors, and it works by prompting the body’s own hormone release rather than by supplying an external hormone.
Does tesamorelin increase testosterone?
Not directly. Its documented effects run through the GH and IGF-1 axis, which is separate from the pathway that regulates testosterone. Some studies have reported changes in sex hormone binding globulin, which can shift free testosterone measurements without changing total production. The womens wellness collection covers compounds studied against hormonal endpoints directly.
Related reading
- Peptides for Weight Loss for Women: what the research covers across the whole category
- How to Reconstitute Peptides: the bench procedure, solvent choice, and stability
- Best Peptides for Women: the full picture, sorted by research goal
- Retatrutide vs Tirzepatide: the incretin side of the weight loss category
Research use only. Every compound referenced on this page is supplied strictly for laboratory research. Nothing here is dosing guidance, and you will not find administration instructions anywhere on this site. These materials are not for human consumption, have not been evaluated by the FDA, and nothing here is medical advice. Consult a qualified healthcare professional for questions about your own health.